DGX

Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know